Since April 2024, Berlin has cemented its place as the spiritual centre of the European cannabis industry. It is home
First published on Cannabis Health On Thursday, 11 June, the first medical cannabis products were prescribed by neurologists at the
The UK’s medical cannabis market has long been a locked box when it comes to reliable data. The fact that
Last year (fiscal year 2024/2025), Canada’s legal cannabis industry recorded revenues of CA$5.5bn, according to the latest figures from Statistics
Germany’s medical cannabis market, which has long been the engine powering Europe’s wider market growth, once again finds itself in
South Africa’s long-suffering cannabis operators have demanded that the government make good on its extensive plans for a regulated framework,
Written by Oskar Fletcher, Chief Executive of pharmaceutical contract manufacturing operator Blossom Pharma. Europe’s medical cannabis industry is entering a
For much of the past five years, the cannabis industry has been defined by disappointment. Public equities are down approximately
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug
As the sun finally dipped over London on the hottest day of the year, the buzz that had filled the
Cannabis Europa London returns on 26-27 May 2026, bringing together operators, investors, clinicians and policymakers from across the global cannabis
As Europe’s medical cannabis market matures, a new category of operator is beginning to emerge. One focused not simply on
Jersey’s medical cannabis industry turned a profit for the first time in 2025, posting revenues of £12m, almost £50m in
Canadian producers shipped 17,067kg of medical cannabis directly to the UK in 2025, more than six times the 2,578kg recorded
Repeal campaigns stall in Arizona as Idaho medical cannabis activists oversubscribe their ballot push, fresh research on legalisation arrests lands, and the industry’s medical-marketing claims and Tilray’s expansion playbook draw scrutiny.
Since President Trump issued an executive order to expedite cannabis rescheduling in December 2025, questions over the legal implications of this
Today’s cannabis news is dominated by rescheduling momentum, with operators racing to secure DEA Schedule III status even as the White House raises fresh concerns over high-potency products, while the UK, Brazil and Idaho underline how rapidly access is broadening on multiple fronts.
Curaleaf Laboratories Becomes First UK Manufacturer of Medical Cannabis Suppositories and Pessaries Curaleaf Laboratories today announced a significant milestone in
We won’t spam you
